Results 21 to 30 of about 112,322 (317)

Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections

Antibiotics, 2022
The treatment of eye infections is very different than treating other body infections that require systemic anti-infectives. Endophthalmitis, keratitis, conjunctivitis, and other ocular infections are treated with direct injection and with topical drops ...
Regis P. Kowalski, Shannon V. Nayyar, Eric G. Romanowski, Vishal Jhanji   +3 more
doaj   +1 more source

Evolution and Biological Evaluation of Matrinic Derivatives with Amantadine Fragments As New Anti-Influenza Virus Agents

Molecules, 2019
A series of novel tricyclic matrinic derivatives with 11-adamantyl substitution were designed, synthesized, and evaluated for their activities against Influenza A H3N2 virus, based on the privileged structure strategy.
Tianyu Niu, Xiaoqiang Zhao, Jing Jiang, Haiyan Yan, Yinghong Li, Sheng Tang, Yuhuan Li, Danqing Song   +7 more
doaj   +1 more source

Phytomedicinal properties of Hygrophila schulli (Neeramulliya) [PDF]

Iranian Journal of Basic Medical Sciences, 2023
Hygrophila schulli which is known as “Neermulli’’ in the vernacular is an herbaceous plant native to Sri Lanka. Ancient medicinal literature suggests the use of H.
Malshani Nissanka, Manjula Weerasekera, Ayomi Dilhari, Ranga Dissanayake, Sajeewa Rathnayake, Gayan Wijesinghe   +5 more
doaj   +1 more source

Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. [PDF]

, 2011
The relaxed complex scheme, a virtual-screening methodology that accounts for protein receptor flexibility, was used to identify a low-micromolar, non-bisphosphonate inhibitor of farnesyl diphosphate synthase.
Cao, Rong, Durrant, Jacob D, Gorfe, Alemayehu A, Li, Jikun, McCammon, J Andrew, Oldfield, Eric, Sankovsky, Anna, Zhu, Wei   +7 more
core   +2 more sources

Linking sustainable use policies to novel economic incentives to stimulate antibiotic research and development

Infectious Disease Reports, 2017
There is now global recognition that antibiotic resistance is an emerging public health threat. Policy initiatives are underway to provide concrete suggestions for overcoming important obstacles in the fight against antibiotic resistance, like the ...
Ursula Theuretzbacher, Christine Årdal, Stephan Harbarth   +2 more
doaj   +1 more source

Broken drug markets in infectious diseases: Opportunities outside the private sector? [PDF]

PLoS Neglected Tropical Diseases, 2019
A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed.
Jonathan D Alpern, Stephen J Dunlop, William M Stauffer   +2 more
doaj   +1 more source

Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]

, 2016
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A., Memish, Ziad A.
core   +1 more source

Factors associated with PPSV23 coverage among older adults in Japan: a nationwide community-based survey

BMJ Open, 2019
Objectives The 23-valent pneumococcal polysaccharide vaccine (PPSV23) was included in Japan’s national immunisation programme for older adults in 2014.
Yoshitaka Murakami, Shinichi Kanazu, Tanaz Petigara, Mari Saito Oba, Yuji Nishiwaki, Akira Watanabe   +5 more
doaj   +1 more source

Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval [PDF]

, 2016
Over the last decade, few novel antibiotics have been approved by the Food and Drug Administration (FDA) for pediatric use. For most anti-infective agents, including antibiotics, extrapolation of efficacy from adults to children is possible if the ...
Benjamin, Daniel K., Brian Smith,, Burckart, Gilbert J., Cohen-Wolkowiez, Michael, Gonzalez, Daniel, Hornik, Christoph P., Mulugeta, Yeruk, Putera, Martin, Zimmerman, Kanecia   +8 more
core   +2 more sources

Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations

Journal of Pharmaceutical Policy and Practice, 2018
Background Antibiotic innovation has dwindled to dangerously low levels in the past 30 years. Since resistance continues to evolve, this innovation deficit can have perilous consequences on patients.
Christine Årdal, Enrico Baraldi, Ursula Theuretzbacher, Kevin Outterson, Jens Plahte, Francesco Ciabuschi, John-Arne Røttingen   +6 more
doaj   +1 more source